Anti-platelet Therapy Resistance – Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities

Open access

Abstract

It is well known that critically ill patients require special attention and additional consideration during their treatment and management. The multiple systems and organ dysfunctions, typical of the critical patient, often results in different patterns of enteral absorption in these patients. Anti-platelet drugs are the cornerstone in treating patients with coronary and cerebrovascular disease. Dual anti-platelet therapy with aspirin and clopidogrel is the treatment of choice in patients undergoing elective percutaneous coronary interventions and is still widely used in patients with acute coronary syndromes. However, despite the use of dual anti-platelet therapy, some patients continue to experience cardiovascular ischemic events. Recurrence of ischemic events is partly attributed to the fact that some patients have poor inhibition of platelet reactivity despite treatment. These patients are considered low- or nonresponders to therapy. The underlying mechanisms leading to resistance are not yet fully elucidated and are probably multifactorial, cellular, genetic and clinical factors being implicated. Several methods have been developed to asses platelet function and can be used to identify patients with persistent platelet reactivity, which have an increased risk of thrombosis. In this paper, the concept of anti-platelet therapy resistance, the underlying mechanisms and the methods used to identify patients with low responsiveness to anti-platelet therapy will be highlighted with a focus on aspirin and clopidogrel therapy and addressing especially critically ill patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Vögtle T Cherpokova D Bender M Nieswandt B. Targeting platelet receptors in thrombotic and thrombo-inflammatory disorders. Hamostaseologie. 2015;35 [Epub ahead of print]

  • 2. Floyd CN Ferro A. Anti-platelet drug resistance: Molecular insights and clinical implications. Prostaglandins Other Lipid Mediat. 2015; [Epub ahead of print]

  • 3. Vlachojannis GJ Dimitropoulos G Alexopoulos D. Clopidogrel resistance: current aspects and future directions. Hell J Cardiol. 2011;52:236-45.

  • 4. Amsterdam EA Wenger NK Brindis RG et al. 2014 AHA/ ACC Guideline for the Management of Patients With Non- ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2014;64:e139-228.

  • 5. Steg PG James SK Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.

  • 6. Pyrgakis VN Goudevenos JA. Clopidogrel and cardiovascular diseases: recommendations for its correct use. Hell J Cardiol. 2010;51:83-6.

  • 7. Angiolillo DJ Fernandez-Ortiz A Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications management and future perspectives. J Am Coll Cardiol. 2007;49:1505-16.

  • 8. Papathanasiou A Goudevenos J TAD. Resistance to Aspirin and Clopidogrel: Possible Mechanisms Laboratory Investigation and Clinical Significance. Hell J Cardiol. 2007;48:352-63.

  • 9. Dupont AG Gabriel DA Cohen MG. Anti-platelet therapies and the role of anti-platelet resistance in acute coronary syndrome. Thromb Res. 2009;124:6-13.

  • 10. Abacı O Kılıçkesmez KO. Aspirin resistance: Where are we now? Anadolu Kardiyol Derg. 2013;13:370-3.

  • 11. Karaźniewicz-Łada M Danielak D Główka F. Genetic and nongenetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother. 2012;13:663-83.

  • 12. Abbate R Crea F De Servi S et al. [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel]. G Ital Cardiol. 2010;11:127-37.

  • 13. Fileti L Campo G Valgimigli M. Latest clinical data on testing for high on-treatment platelet reactivity. Rev Cardiovasc Med. 2011;12(Suppl 1):S14-22.

  • 14. Saraf S Bensalha I Gorog DA. Anti-platelet Resistance - Does it Exist and How to Measure it ? Clin Med Cardiol. 2009;3:77-91.

  • 15. Ahluwalia K Bhanwra S. Anti-platelet therapy: present status and its future directions. Int J Basic Clin Pharmacol. 2014;3:260.

  • 16. Patrono C Coller B FitzGerald G A. Hirsh J Roth G. Plateletactive drugs: The relationships among dose effectiveness and side effects - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Supl).

  • 17. Bagoly Z Sarkady F Magyar T et al. Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy. PLoS One. 2013;8:1-11.

  • 18. Huang B Huang Y Li Y et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43:212-24.

  • 19. Bonello L Tantry US Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.

  • 20. Mallouk N Labruyère C Reny J-L et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost. 2012;107:494-506.

  • 21. Aradi D Komócsi A Vorobcsuk A et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160:543-51.

  • 22. Combescure C Fontana P Mallouk N et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:923-33.

  • 23. Sofi F Marcucci R Gori AM Giusti B Abbate R Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: An updated meta-analysis. Thromb Haemost. 2010;103:841-8.

  • 24. Brar SS Ten Berg J Marcucci R et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945-54.

  • 25. Hankey GJ Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606-17.

  • 26. Topçuoglu MA Arsava EM Ay H. Anti-platelet resistance in stroke. Expert Rev Neurother. 2011;11:251-63.

  • 27. Schwartz KA Schwartz DE Barber K Reeves M De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med. 2008;6:46.

  • 28. Serebruany V Cherala G Williams C et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J. 2009;158:925-32.

  • 29. Herlitz J Tóth PP Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125-41.

  • 30. Grosser T Fries S Lawson JA Kapoor SC Grant GR FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377-85.

  • 31. Feher G Feher A Pusch G et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol. 2010;2:171-86.

  • 32. Mansour K Taher AT Musallam KM Alam S. Aspirin resistance. Adv Hematol. 2009;2009:1-10.

  • 33. Scott SA Owusu Obeng A Hulot J-S. Anti-platelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:175-89.

  • 34. Johnson DA Chilton R Liker HR. Proton-pump inhibitors in patients requiring anti-platelet therapy: new FDA labeling. Postgrad Med. 2014;126:239-45.

  • 35. Juurlink DN Gomes T Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-8.

  • 36. Stockl KM. Risk of Rehospitalization for Patients Using Clopidogrel With a Proton Pump Inhibitor. Arch Intern Med. 2010;170:704.

  • 37. Neubauer H Günesdogan B Hanefeld C Spiecker M Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - A flow cytometry study. Eur Heart J. 2003;24:1744-9.

  • 38. Park Y Jeong Y-H Tantry US et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J. 2012;33:2151-62.

  • 39. Pelliccia F Rosano G Marazzi G et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti-platelet therapy. Circ J. 2014;78:679-84.

  • 40. Hedegaard SS Hvas A-M Grove EL et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res. 2009;124:96-100.

  • 41. Ojeifo O Wiviott SD Antman EM et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio. JACC Cardiovasc Interv. 2013;6:1275-81.

  • 42. Katoh M Nakajima M Shimada N Yamazaki H Yokoi T. Inhibition of human cytochrome P450 enzymes by 14-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843-52.

  • 43. Seo K-D Kim YD Yoon Y-W Kim J-Y Lee K-Y. Anti-platelet effect of clopidogrel can be reduced by calcium-channel blockers. Yonsei Med J. 2014;55:683-8.

  • 44. Feher G Feher A Pusch G Lupkovics G Szapary L Papp E. The genetics of anti-platelet drug resistance. Clin Genet. 2009;75:1-18.

  • 45. Goodman T Ferro A Sharma P. Pharmacogenetics of aspirin resistance: A comprehensive systematic review. Br J Clin Pharmacol. 2008;66: 222-32.

  • 46. Altman R Flockhart D Goldstein D. Principles of pharmacogenetics and pharmacogenomics. 1st ed. 2012;121-4.

  • 47. Negovan A Voidăzan S Pantea M et al. AGT A-20C (rs5050) gene polymorphism and ulcer occurrence in patients treated with low-dose aspirin: a case-control study. Rev Romana Med Lab. 2015;23:179-87.

  • 48. Kazui M Nishiya Y Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9.

  • 49. Kim KA Park PW Hong SJ Park J-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-42.

  • 50. Mega JL Close SL Wiviott SD et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009;360:354-62.

  • 51. Varenhorst C James S Erlinge D et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirintreated patients with coronary artery disease. Eur Heart J. 2009;30:1744-52.

  • 52. Simon T Céline V Murielle M-K et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med. 2009;360:363-75.

  • 53. Seip RL Duconge J Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010;6:409-24.

  • 54. Militaru FC Vesa ŞC Crişan S Militaru V Trifa AP Buzoianu AD. Genotype-phenotype correlations in patients treated with acenocoumarol. Rev Romana Med Lab. 2014;22:347-54.

  • 55. Limdi NA Wiener H Goldstein JA Acton RT Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. 2009;43:119-28.

  • 56. Michelson AD Cattaneo M Eikelboom JW Gurbel P. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Haemostasis. 2005;3:1309-11.

  • 57. Gasparyan AY Watson T Lip GYH. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51:1829-43.

  • 58. Nguyen NQ Chapman MJ Fraser RJ et al. The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. Intensive Care Med. 2008;34:454-60.

  • 59. Hong J-Y Oh JI. Effects of preoperative anxiety on gastric fluid acidity and volume. J Korean Med Sci. 2005; 20:232-5.

  • 60. Roush J a. The role of the stomach in drug absorption as observed via absorption rate analysis. Int J Pharm. 2014;471:112-7.

  • 61. Ganesan S Williams C Maslen CL Cherala G. Clopidogrel variability: role of plasma protein binding alterations. Br J Clin Pharmacol. 2013;75:1468-77.

  • 62. Storm C Schefold JC Kerner T et al. Prehospital cooling with hypothermia caps (PreCoCa): A feasibility study. Clin Res Cardiol. 2008;97:768-72.

  • 63. Bjelland TW Hjertner Ø Klepstad P Kaisen K Dale O Haugen BO. Anti-platelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010;81:1627-31.

  • 64. Součková L Opatřilová R Suk P et al. Impaired bioavailability and anti-platelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69:309-17.

  • 65. Ogu CC Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000;13:421-3.

  • 66. Pascoe MC Howells DW Crewther DP et al. Fish oil diet associated with acute reperfusion related hemorrhage and with reduced stroke-related sickness behaviors and motor impairment. Front Neurol. 2014;5:14.

  • 67. Wachira JK Larson MK Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111:1652-62.

  • 68. Bradnam V White R. Handbook of Drug Administration Via Enteral Feeding Tubes 3rd edition London UK: Pharmaceutical Press; 2015.

  • 69. Powers JE Cascella PJ. Comparison of methods used to prepare tablets for nasogastric tube administration. J Pharm Technol. 1990;6:60-2.

  • 70. Patel V Kukadiya H Mashru R Surti N Mandal S. Development of microemulsion for solubility enhancement of clopidogrel. Iran J Pharm Res IJPR. 2010;9:327-34.

  • 71. Lenk E Spannagl M. Platelet function testing - guided antiplatelet therapy. J Int Fed Clin Chem Lab Med. 2013;24:1-7.

  • 72. Breet NJ Werkum JW van Bouman HJ et al. Comparison of Platelet Function Tests Undergoing Coronary Stent Implantation. JAMA. 2010;303:754-62.

  • 73. Paniccia R. Assessment of platelet function: Laboratory and point-of-care methods. World J Transl Med. 2014;3:69.

  • 74. Gladding P Webster M Ormiston J Olsen S White H. Antiplatelet drug nonresponsiveness. Am Heart J. 2008;155:591-9.

  • 75. Tousoulis D Siasos G Stefanadis C. Aspirin resistance: what the cardiologist needs to know? Int J Cardiol. 2009;132:153-6.

  • 76. Michelson AD. Platelets. 2nd ed. 2007;545-63.

  • 77. Gachet C Aleil B. Testing anti-platelet therapy. Eur Hear J Suppl. 2008;10(Suppl A):A28-34.

  • 78. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3-10.

  • 79. Hayward CPM Harrison P Cattaneo M Ortel TL Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312-9.

  • 80. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008;34:709-33.

  • 81. Hussein HM Emiru T Georgiadis AL Qureshi AI. Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures. Am J Neuroradiol. 2013;34:700-6.

  • 82. Aradi D Storey RF Komócsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-15.

  • 83. Meybohm P Zacharowski K Weber CF. Point-of-care coagulation management in intensive care medicine. Crit Care. 2013;17:218.

  • 84. Adamzik M Gorlinger K Peters J Hartmann M. Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis. Crit Care. 2012;16:R204.

  • 85. Short S Kram B Taylor S Cheng J Ali K Vasquez D. Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. J Trauma Acute Care Surg. 2013;74:1419-24.

  • 86. Clareus A Fredriksson I Wallén H Gordon M Stark A Sköldenberg O. Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patients. World J Orthop. 2015;6:439-45.

  • 87. Rosengart TK Romeiser JL White LJ et al. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. J Thorac Cardiovasc Surg. 2013;146:1259-66 1266.e1; discussion 1266.

  • 88. Mishra P Thekkudan J Sahajanandan R et al. The role of point-of-care assessment of platelet function in predicting postoperative bleeding and transfusion requirements after coronary artery bypass grafting. Ann Card Anaesth. 2015;18:45.

  • 89. Sibbing D Braun S Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849-56.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 377 149 14
PDF Downloads 140 60 6